Core Points - Hemostemix Inc has completed a non-brokered private placement, raising gross proceeds of $2,969,600 from the sale of 29,696,000 units at a price of $0.10 per unit [1][2] - Each unit consists of one common share and one common share purchase warrant, with the warrants exercisable at $0.15 for two years, subject to an acceleration clause [2] - The proceeds will be used for the repayment of a debt at a 50% discount and for general working capital to support operational expenses, including marketing of VesCell™ [4] Financial Details - The company paid approximately $97,600 in cash finder fees and issued 976,000 finder's options at an exercise price of $0.15 [3] - The offering is classified as a related party transaction, with directors participating, and the company will file a material change report as required [5] Shareholder Information - Prior to the offering, Mr. Peter Lacey owned 9,316,937 common shares, representing 6.14% on a partially diluted basis; after subscribing to 15,000,000 units, he now owns 24,316,937 shares, equating to 13.40% on a non-diluted basis [6] Stock Options - The company granted 3,870,000 stock options to directors, officers, employees, and consultants at an exercise price of $0.13, expiring on July 23, 2030 [9] - After this issuance, the total outstanding options amount to 18,111,694 [9] Company Overview - Hemostemix is an autologous stem cell therapy platform company, recognized for its patented VesCell™ therapy, which has shown promising results in clinical studies for various cardiovascular conditions [10]

Core Insights - Hemostemix Inc. has successfully closed the sale of 15 ACP-01 Therapy Convertible Debentures, raising proceeds of USD $517,230, pending TSXV Exchange approval [1][2] - The CEO of Hemostemix, Thomas Smeenk, emphasized that the approval of the Therapy Convertible Debenture (TCD) marks a significant advancement for the company, allowing for the sale of VesCell therapy to clinics, investors, and high net worth individuals [2] - The TCD is designed to streamline production and treatment schedules, enabling rapid scaling without diluting shareholder equity, positioning Hemostemix as a leader in autologous stem cell therapy for cardiovascular diseases [2] Company Overview - Hemostemix is an autologous stem cell therapy company founded in 2003, recognized as a World Economic Forum Technology Pioneer [5] - The company has treated 498 patients and completed seven clinical studies involving 318 subjects, with results published in nine peer-reviewed publications [5] - Hemostemix's ACP-01 therapy is clinically relevant and statistically significant for various cardiovascular conditions, including peripheral arterial disease and chronic limb threatening ischemia [5] Financial Details - Each TCD is convertible into an ACP-01 therapy and can be converted into common shares at a price of $0.155 per share, with an interest rate of 6% per annum payable in shares [3] - The proceeds from the TCD will be allocated for general working capital, corporate overhead, and research and development activities [4] - The company paid CA$59,171 and issued 356,298 Finder's Warrants to a finder in connection with the TCD offering, allowing the purchase of common shares at $0.155 per share [4]

Core Points - Hemostemix Inc has announced a non-brokered private placement increasing gross proceeds to $3,000,000 due to oversubscriptions [1] - Each Unit in the placement is priced at $0.10 and includes one Common Share and one Warrant, with the Warrant exercisable at $0.15 for two years [2] - Certain directors of Hemostemix are participating in the Offering, which is classified as a related party transaction under MI 61-101 [3] Financial Details - The proceeds from the private placement will be used to repay CD1 at a 50% discount to face value ($1,250,000) and for general working capital [4] - The Company has a history of clinical studies, with seven studies involving 318 subjects, demonstrating the efficacy of its VesCell™ therapy [5] Company Overview - Hemostemix is focused on autologous stem cell therapy and has developed VesCell™ (ACP-01), which has shown significant clinical results in treating various cardiovascular conditions [5] - The Company has received recognition as a Technology Pioneer by the World Economic Forum and has published results in ten peer-reviewed publications [5]

Summary of Biocardia (BCDA) FY Conference Call Company Overview - Biocardia is a late-stage development company focused on autologous stem cell therapy for ischemic heart failure and chronic myocardial ischemia, located in Sunnyvale, California [1][2][5] - The company has four clinical programs at various stages of advancement [5] Core Points and Arguments Heart Failure Program - The lead indication is heart failure, specifically the BCDA DAO one cardiac phase three trial [6] - Heart failure is described as an enormous unmet medical need, with the therapy aiming to treat microvascular dysfunction by delivering high dosages of autologous cells directly into the heart muscle [6][7] - Preclinical models have shown that the therapy can reduce fibrosis and enhance capillary density [7] - The therapy includes a selection diagnostic to screen out patients who are not appropriate for treatment [7][8] Clinical Trial Data - In March, data from the heart failure one trial was presented, showing reduced mortality and improved quality of life, despite not hitting the primary endpoint [10][11] - The trial involved 115 patients and demonstrated statistical significance in secondary endpoints, including survival and reduction in major adverse cardiac events [11][12] - A one-time dosage of cells is administered, with a two-year follow-up showing robust effects [12] Upcoming Trials and Regulatory Submissions - The FDA approved a subsequent trial (Heart Failure II) to address previous enrollment challenges, with modifications to the study design [14][15] - The new trial will focus on patients with elevated markers of heart stress and aims to double the enrollment rate [19] - Biocardia is pursuing expedited approval from Japan's PMDA for cardiac cell therapy, with a submission expected within the year [21][24] - The company is also working on FDA submissions for its delivery system, which has shown excellent safety data [25] Chronic Myocardial Ischemia Program - The CardiAmp CMI program targets chronic myocardial ischemia with refractory angina, a condition poorly met by existing therapies [26][28] - There are at least one million patients in the U.S. with this condition, and Biocardia's approach aims to be the least expensive cardiac cell therapy available [30][31] - The company is working on a manuscript for early data from the low dose cohort of the CMI trial [32] Other Important Information - Biocardia has an allogeneic platform and is exploring partnerships for both cardiac and pulmonary indications [38][40] - The partnership environment is currently challenging due to market stability concerns, but Biocardia's assets are proven and in the clinic [41] - The company is focused on advancing its lead program while also exploring opportunities in other areas [39][41]